Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
The skin is a mirror of our body's condition
BPC-157 repairs mucosal lining damage caused by NSAIDs (ibuprofen and aspirin), alcohol, and inflammatory bowel conditions by promoting mucosal cell regeneration and modulating gut-associated cytokines in the digestive system
A broader mechanistic review by Seiwerth and colleagues in Current Pharmaceutical Design laid out how BPC-157 seems to borrow the same angiogenic and growth-factor pathways the body uses to heal the gut, and apply them to tendon, ligament, muscle, and bone (Seiwerth et al., 2018)
What this means for you right now: BPC-157 and TB-500 are currently available through licensed compounding pharmacies under clinician supervision Thymosin Alpha-1 has a longer regulatory history and a more established compounding track record Sourcing from unregulated vendors carries real safety risks contamination, misdosing, and no quality control We've covered the full regulatory picture in detail here: PCAC Peptide Review 2026: What the July Advisory Panel Decision Means for BPC-157, TB-500, and Thymosin Alpha-1 What a Clinician-Supervised Long COVID Peptide Protocol Looks Like A responsible protocol starts with assessment not assumption
162 ShangJ.DeguchiK.OhtaY.LiuN.ZhangX.TianF.et al (2011)
US$ 24.43
US$ 20.53
US$ 26.77
US$ 21.09
US$ 23.72
US$ 29.29
US$ 21.28
US$ 24.55
US$ 28.07
US$ 24.84